SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

A sharp AVAX rebound is drawing attention around the institutional-adoption narrative, particularly traders focus on reported NYSE/ICE testing of Avalanche for tokenized securities and expanded brokerage access. Bulls view this as validation for real-world-asset growth, while skeptics argue the move is a pump-and-dump and cite weak fee revenue and token inflation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Escalating U.S.-Iran tensions, potential military action or a negotiated deal, and related risks to the Strait of Hormuz and oil supplies are dominating discussion around SPY. Traders are divided, with some expecting higher volatility and downside from energy inflation and rising yields, while others argue a ceasefire or dealand resilient futurescould support a continued rally.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Speculation around the U.S. CLARITY Act and broader crypto regulatory treatment is driving attention, with traders debating whether passage would support HBAR and other altcoins or whether delays and failure would trigger another selloff. The discussion is amplified by HBARs choppy rebound and resistance, while some holders cite Hederas institutional partnerships and network growth as longer-term support despite limited price follow-through.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Renewed U.S.-Iran and Houthi-Saudi tensions, with potential oil-supply disruption, are driving heavy debate around QQQs near-term direction. Bulls point to resilient futures and continued semiconductor/AI momentum, while bears warn that higher oil prices, Treasury yields and weak market breadth could trigger a pullback.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

A rebound through a key round-number resistance level has renewed attention around ALGO, with traders citing stronger volume, bullish chart setups and a potential altcoin-season rotation. Bullish participants also point to new leadership and post-quantum network upgrades, while skeptics argue the move may fade amid weak adoption, dilution concerns and recurring selloffs.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

The launch of confidential perpetual contracts powered by Hyperliquid is being cited as the immediate catalyst behind NEARs sharp rally, with traders highlighting privacy for leveraged on-chain trading. The community is broadly bullish and pointing to NEARs AI, interoperability and privacy positioning, although some traders argue the move is mainly momentum, short covering or a liquidity-driven pump.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Geopolitical risk around the Iran conflict, Houthi attacks, Strait of Hormuz shipping and damage to Saudi oil infrastructure is driving intense crude and USO discussion. Traders remain split, with bulls citing potential supply disruptions while bears argue that de-escalation, pipeline restarts, inventory builds and demand destruction could unwind the risk premium.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Anticipation around Coherents PhotonLink platform unveiling at ECOC, alongside strong AI data-center demand for optical connectivity and Nvidia-related supply ties, is driving attention. Traders are broadly bullish on a recovery, though some caution that resistance, profit-taking and sector volatility could limit follow-through.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

Attention centers on REalloys selection for exclusive negotiations with the U.S. Army to develop heavy rare-earth processing at Utahs Tooele Army Depot, alongside its broader strategy to build a non-Chinese rare-earth magnet supply chain ahead of 2027 defense-sourcing requirements. Bullish traders cite the defense-policy backdrop, strategic partnerships and reported institutional interest, while skeptics focus on execution risk, dilution, limited current production and the absence of recent company updates.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Elevated crude prices and supply-risk concerns from Middle East tensions, including attacks on Saudi energy infrastructure and disruption around the Strait of Hormuz, are driving attention to Exxon Mobil and other major energy stocks. Traders largely view the oil rally as a tailwind for upstream cash flow, while others warn that de-escalation or a return of disrupted supply could unwind the geopolitical premium and pressure shares.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and

Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus...

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat PR Newswire STATEN ISLAND...

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update PR Newswire STATEN ISLAND, N.Y., Aug. 14, 2026 STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx...

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics PR Newswire STATEN ISLAND, N.Y., Aug. 12, 2026 STATEN...

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor...

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurre

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection FDA Provides...

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile...

Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update

Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update PR Newswire STATEN ISLAND...

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference Acurx Pharmaceuticals Announces Presentation of Results from Leiden...

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Acurx Pharmaceuticals Inc

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Microsoft Corp

Meta Platforms Inc

SELLAS Life Sciences Group Inc

Alphabet Inc Class A

CoreWeave Inc

SpaceX

Stocktwits Polls

$ACXP   "We continue to identify and pursue funding opportunities for our Phase 3 ASPIRE trial for the treatment of both acute CDI and a reduction of recurrence. We have several initiatives underway to this end and will report our progress in future updates."

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACXP Acurx Pharmaceuticals Inc

Fundamentals

Latest ACXP News